Navigation Links
Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
Date:10/8/2008

REDMOND, Wash., Oct. 8 /PRNewswire/ -- Archus Orthopedics, Inc. today announced the first human use of its facet replacement technology to complement an artificial disc. The landmark case was performed by Dr. Karin Buttner-Janz, Dr. Hansen Yuan and Dr. Friedrich Kleinod at the Vivantes Clinic in Berlin, Germany, and involved a patient who previously underwent disc replacement surgery and later developed symptomatic facet joint degeneration. "Generally in this situation the patient is converted to spine fusion," said Dr. Karin Buttner-Janz. "With the Archus facet replacement system, we are now able to allow these patients to keep their artificial disc, retain motion, and avoid fusion," she added.

Artificial discs are implanted in patients whose natural disc has degenerated over time, resulting in chronic back pain. Historically, these patients have been treated by spine fusion surgery. Disc replacement surgery has demonstrated equivalent clinical benefit and has the added advantage of restoring normal motion to the spine. Currently, two artificial discs are approved by the Food and Drug Administration for sale in the United States, and a third disc is nearing approval. Industry analysts project rapid adoption of artificial discs once broader reimbursement is obtained.

While artificial discs represent an attractive alternative to spine fusion, they are not applicable to all patients. Many potential disc recipients are contraindicated because they also exhibit evidence of facet joint degeneration. These patients are, instead, treated by conventional spine fusion because it addresses both the disc and facet issues. In addition, since spine degeneration is often a progressive disease, some artificial disc recipients return later with degenerative facet joint problems that require revision to spine fusion. "In both scenarios, the primary issue is facet joint degeneration resulting in the need to fuse the patient, either immediately or later," said Dr. Hansen Yuan, who spearheaded development of the company's unique product family to compliment artificial discs. "Replacing the degenerative facet joint and maintaining spine motion is a much better solution than fusion," he added.

"Combining disc or nucleus replacement therapy with facet replacement expands the market for these technologies and gives surgeons all the tools they need to rebuild the entire spinal segment," said Jim Fitzsimmons, chairman and chief executive officer. "This total joint replacement approach is consistent with where things have gone in orthopedics and where they are ultimately going in spine," he added. Archus indicated that its entire family of facet replacement products has already received CE Mark approval in the European Union, where marketing trials are ongoing.

About Archus Orthopedics

Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. The company's first product, the Total Facet Arthroplasty System(R), has been successfully implanted in hundreds of patients worldwide, and is being evaluated in the United States in a Pivotal IDE clinical trial approved by the U.S. Food and Drug Administration. Archus has received venture capital funding from MPM Capital, InterWest Partners, Polaris Venture Partners and Johnson & Johnson Development Corporation.


'/>"/>
SOURCE Archus Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ascension Orthopedics Closes $21 Million Financing and Recruits an Orthopedics Industry Veteran as CEO
2. Ascension Orthopedics Launches the TITAN(TM) Humeral Resurfacing Device World Wide
3. Elsevier expands Procedures Consult with emergency medicine, orthopedics and anesthesia procedures
4. Three Industry Veterans Join Ascension Orthopedics
5. Central DuPage Hospitals Orthopedics Ranks in U.S. News Media Groups 2008 Edition of Americas Best Hospitals for the Second Consecutive Year
6. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
7. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
8. U of M performs first systemic therapy for fatal childhood disease
9. COURAGE Sub-study: PCI Outperforms Drugs-Only
10. PET outperforms CT in characterization of lung nodules
11. ADAMS Performs Management Services for University Hospitals $600 Million Expansion/Renovation Program in Cleveland, OH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the ... management solution to the exhibit floor for the 2017 HIMSS Conference & ... From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets ... ESSA Pharma Inc. (Nasdaq: EPIX ). The ... Kumar Raja , PhD. ESSA Pharmaceuticals ... castration resistant prostate cancer (CRPC). Its lead compound EPI-506, ... the amino-terminal domain of the androgen receptor, thereby has ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today announced results ... Net income attributable to DaVita Inc. for the ... or $0.80 per share and $880 million, or $4.29 per ... DaVita Inc. for the quarter and year ended December 31, ... or $0.98 per share, and $789 million, or $3.85 per ...
Breaking Medicine Technology: